3-(6-[[1-(2,2-Difluoro-benzo[1,3]dioxol-5-yl)-cyclopropanecarbonyl]-amino]-3-methyl-pyridin-2-yl)-benzoic acid
| Title | Journal |
|---|---|
| Role of CFTR in epithelial physiology. | Cellular and molecular life sciences : CMLS 20170101 |
| Lumacaftor-ivacaftor (Orkambi) for cystic fibrosis: behind the 'breakthrough'. | Evidence-based medicine 20160601 |
| Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects. | Therapeutic advances in respiratory disease 20151201 |
| Cystic fibrosis - a multiorgan protein misfolding disease. | Future science OA 20150901 |
| A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. | The Lancet. Respiratory medicine 20140701 |
| VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1. | Molecular biology of the cell 20131001 |
| Mechanism-based corrector combination restores ΔF508-CFTR folding and function. | Nature chemical biology 20130701 |
| Functional rescue of a kidney anion exchanger 1 trafficking mutant in renal epithelial cells. | PloS one 20130101 |
| Ivacaftor potentiation of multiple CFTR channels with gating mutations. | Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 20120501 |
| Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment. | The Annals of pharmacotherapy 20120101 |
| Cystic fibrosis transmembrane regulator protein mutations: 'class' opportunity for novel drug innovation. | Paediatric drugs 20070101 |
| Pharmacotherapy of the ion transport defect in cystic fibrosis: role of purinergic receptor agonists and other potential therapeutics. | American journal of respiratory medicine : drugs, devices, and other interventions 20030101 |